Compare LESL & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LESL | PHGE |
|---|---|---|
| Founded | 1963 | 2015 |
| Country | United States | United States |
| Employees | N/A | 57 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 15.7M |
| IPO Year | 2020 | N/A |
| Metric | LESL | PHGE |
|---|---|---|
| Price | $4.63 | $0.72 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $2.54 | N/A |
| AVG Volume (30 Days) | 2.5M | ★ 9.3M |
| Earning Date | 05-18-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,241,915,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $0.25 |
| 52 Week High | $6.92 | $8.50 |
| Indicator | LESL | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 66.64 | 39.24 |
| Support Level | $3.50 | $0.41 |
| Resistance Level | $6.92 | $1.89 |
| Average True Range (ATR) | 0.65 | 0.23 |
| MACD | 0.15 | 0.06 |
| Stochastic Oscillator | 77.11 | 23.25 |
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products, including chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company serves residential pool, residential spa, professional pool, and commercial pool consumers and markets its products through over 1,000 company-operated locations in 39 states and e-commerce websites, operating only in the United States. It operates mainly in the pool and spa aftermarket industry and offers regularly purchased, non-discretionary maintenance items, along with installation and repair services for pool and spa equipment.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).